ClinicalTrials.gg
CompletedNCT02672423Updated Jan 4, 2019Results posted

A Study of Abemaciclib in Healthy Participants

A Phase 1 interventional study of Abemaciclib Capsules (Reference Formulation) and Abemaciclib Tablet (Test Formulation) in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to measure how much abemaciclib gets into the blood stream and how long it takes the body to get rid of it when given as capsules versus a tablet(s). The effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information about any side effects that may occur will also be collected.

This study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B will last about 60 days including follow-up. Screening may occur up to 28 days before the first dose of study drug. Participants are only allowed to enroll in one part.

This study is for research purposes only and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy surgically sterile or females and sterile males
  • Have a (BMI) 18 to 32 kilograms per square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to abemaciclib, related compounds, or any components of the formulation
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Abemaciclib Part A

    Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.

    Drug: Abemaciclib Capsules (Reference Formulation) · Drug: Abemaciclib Tablet (Test Formulation)

  • Experimental
    Abemaciclib Part B

    R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.

    Drug: Abemaciclib Capsules (Reference Formulation) · Drug: Abemaciclib Tablet (Test Formulation)

  • Experimental
    Abemaciclib Part C

    T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.

    Drug: Abemaciclib Tablet (Test Formulation)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])

    Area under the concentration versus time curve from zero to infinity.

    Time frame: Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose

  2. PK: Maximum Observed Drug Concentration (Cmax)

    Maximum observed drug concentration.

    Time frame: Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose

07

Results

Posted Aug 3, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestonePart A: Abemaciclib (R,T150 )Part A: Abemaciclib (T150,R)Part B: Abemaciclib (R,T150,T50 )Part B: Abemaciclib (T150,T50,R)Part B: Abemaciclib (T50,R,T150)Part B: Abemaciclib (R,T50,T150)Part B: Abemaciclib (T150,R,T50)Part B: Abemaciclib (T50,T150,R)Part C: Abemaciclib (T150 Fed, T150 Fasted)Part C: Abemaciclib (T150 Fasted, T150 Fed)
Started771415151515151212
Received at least one dose of study drug771415151515151212
Completed771415141515151212
Not completed0000100000
Withdrew: Adverse event0000100000
Washout 1
Participant flow — Washout 1
MilestonePart A: Abemaciclib (R,T150 )Part A: Abemaciclib (T150,R)Part B: Abemaciclib (R,T150,T50 )Part B: Abemaciclib (T150,T50,R)Part B: Abemaciclib (T50,R,T150)Part B: Abemaciclib (R,T50,T150)Part B: Abemaciclib (T150,R,T50)Part B: Abemaciclib (T50,T150,R)Part C: Abemaciclib (T150 Fed, T150 Fasted)Part C: Abemaciclib (T150 Fasted, T150 Fed)
Started771415141515151212
Completed771415141515151212
Not completed0000000000
Period 2
Participant flow — Period 2
MilestonePart A: Abemaciclib (R,T150 )Part A: Abemaciclib (T150,R)Part B: Abemaciclib (R,T150,T50 )Part B: Abemaciclib (T150,T50,R)Part B: Abemaciclib (T50,R,T150)Part B: Abemaciclib (R,T50,T150)Part B: Abemaciclib (T150,R,T50)Part B: Abemaciclib (T50,T150,R)Part C: Abemaciclib (T150 Fed, T150 Fasted)Part C: Abemaciclib (T150 Fasted, T150 Fed)
Started771415141515151212
Completed771315141515151212
Not completed0010000000
Withdrew: Withdrawal by subject0010000000
Washout 2
Participant flow — Washout 2
MilestonePart A: Abemaciclib (R,T150 )Part A: Abemaciclib (T150,R)Part B: Abemaciclib (R,T150,T50 )Part B: Abemaciclib (T150,T50,R)Part B: Abemaciclib (T50,R,T150)Part B: Abemaciclib (R,T50,T150)Part B: Abemaciclib (T150,R,T50)Part B: Abemaciclib (T50,T150,R)Part C: Abemaciclib (T150 Fed, T150 Fasted)Part C: Abemaciclib (T150 Fasted, T150 Fed)
Started771315141515151212
Completed771315141515151212
Not completed0000000000
Period 3
Participant flow — Period 3
MilestonePart A: Abemaciclib (R,T150 )Part A: Abemaciclib (T150,R)Part B: Abemaciclib (R,T150,T50 )Part B: Abemaciclib (T150,T50,R)Part B: Abemaciclib (T50,R,T150)Part B: Abemaciclib (R,T50,T150)Part B: Abemaciclib (T150,R,T50)Part B: Abemaciclib (T50,T150,R)Part C: Abemaciclib (T150 Fed, T150 Fasted)Part C: Abemaciclib (T150 Fasted, T150 Fed)
Started0013151415151500
Completed0013151414151400
Not completed0000010100
Withdrew: Withdrawal by subject0000000100
Withdrew: Physician decision0000010000

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])

Area under the concentration versus time curve from zero to infinity.

Time frame:
Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose
Reported as:
Geometric mean · Nanograms*hour/milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
Nanograms*hour/milliliter (ng*hr/mL)Part A: 150 mg Abemaciclib (T150)Part A: 3 x 50 mg Abemaciclib (R)Part B: 150 mg Abemaciclib (T150)Part B: 3 x 50 mg Abemaciclib (T50)Part B: 3 x 50 mg Abemaciclib (R)Part C: 150 mg Abemaciclib (Fed)Part C: 150 mg Abemaciclib (Fasted)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])3080 ± 572880 ± 563110 ± 553120 ± 523130 ± 594170 ± 493590 ± 45
PrimaryPK: Maximum Observed Drug Concentration (Cmax)

Maximum observed drug concentration.

Time frame:
Parts A and C Periods 1 and 2; Part B Periods 1, 2, 3: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 96, 120,144,168 and 192 hours postdose
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
PK: Maximum Observed Drug Concentration (Cmax)
Nanograms per milliliter (ng/mL)Part A: 150 mg Abemaciclib (T150)Part A: 3 x 50 mg Abemaciclib (R)Part B:150 mg Abemaciclib (T150)Part B: 3 x 50 mg Abemaciclib (T50)Part B: 3 x 50 mg Abemaciclib (R)Part C:150 mg Abemaciclib (Fed)Part C:150 mg Abemaciclib (Fasted)
PK: Maximum Observed Drug Concentration (Cmax)104 ± 52101 ± 5695.2 ± 4897.7 ± 5095.8 ± 51130 ± 4499.6 ± 36

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 3 x 50 mg (R)—0/14 (0%)7/14 (50%)
Part A: 1 x 150 mg (T150)—0/14 (0%)6/14 (42.9%)
Part B: 3 x 50 mg (R)—0/88 (0%)21/88 (23.9%)
Part B 1 x 150 mg (T150)—0/87 (0%)17/87 (19.5%)
Part B 3 x 50 mg (T50)—0/88 (0%)22/88 (25%)
Part C: (T150 Fed, T150 Fasted)—0/24 (0%)3/24 (12.5%)
Part C: (T150 Fasted, T150 Fed)—0/24 (0%)1/24 (4.2%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPart A: 3 x 50 mg (R)Part A: 1 x 150 mg (T150)Part B: 3 x 50 mg (R)Part B 1 x 150 mg (T150)Part B 3 x 50 mg (T50)Part C: (T150 Fed, T150 Fasted)Part C: (T150 Fasted, T150 Fed)
NauseaGastrointestinal disorders3/144/148/889/8712/883/240/24
DiarrhoeaGastrointestinal disorders2/141/144/885/875/880/241/24
VomitingGastrointestinal disorders2/141/144/884/875/881/240/24
FatigueGeneral disorders2/140/141/881/871/880/240/24
DizzinessNervous system disorders2/141/140/881/872/881/240/24
HeadacheNervous system disorders2/141/1411/887/877/882/240/24
Abdominal painGastrointestinal disorders1/140/142/883/874/880/241/24
ConstipationGastrointestinal disorders1/140/141/881/874/880/240/24
Gastrooesophageal reflux diseaseGastrointestinal disorders1/141/141/880/871/880/240/24
Back painMusculoskeletal and connective tissue disorders0/141/141/880/871/880/240/24

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Part A: AbemaciclibPart B AbemaciclibPart C AbemaciclibTotal
Mean53.6 ± 16.951.8 ± 11.655.5 ± 10.652.7 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Part A: AbemaciclibPart B AbemaciclibPart C AbemaciclibTotal
Female117821110
Male311317
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: AbemaciclibPart B AbemaciclibPart C AbemaciclibTotal
Hispanic or Latino4241038
Not Hispanic or Latino10651489
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: AbemaciclibPart B AbemaciclibPart C AbemaciclibTotal
American Indian or Alaska Native0112
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American313016
White96922100
More than one race2619
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Part A: AbemaciclibPart B AbemaciclibPart C AbemaciclibTotal
United States148924127
08

Study locations

2 sites
  • Daytona Beach Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Evansville Clinical Research Unit
    Evansville, Indiana 47710, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Oct 2016 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2016
First posted
Feb 3, 2016
Start
Feb 2016
Primary completionActual
Oct 2016
CompletionActual
Oct 2016
Results first posted
Aug 3, 2018
Last update
Jan 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02672423
Responsible party
Sponsor
First posted
Feb 3, 2016
Start date
Feb 2016
Primary completion
Oct 2016
Completion
Oct 2016
Results posted
Aug 3, 2018
Last update
Jan 4, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion